Additional Dosage Routes
What is the Additional Dosage Routes Module?
The Additional Dosage Routes Module in GastroPlus extends the program beyond the traditional oral and intravenous drug administration routes. With this module, you can simulate mechanistic absorption and disposition through dermal (topical and subcutaneous), intraoral (oral cavity), pulmonary (intranasal and respiratory), ocular, and NEW! intramuscular routes. These models were all developed in collaboration with top 5 pharmaceutical companies and/or the U.S. FDA. The ability to predict concentration profiles in different regions of the skin, mouth, eye, lungs, nose, and muscle can help you:
- Explore various formulation/drug delivery options to achieve desired therapeutic effects
- Identify species-specific changes to estimate how a drug is handled in animals vs. humans
With the Additional Dosage Routes Module, simulating concentrations through these sites is managed through our easy-to-use interface. Mechanistic, physiologically-based models are provided for each tissue, for different species. You can also customize your own physiology by entering available information into the program. These models are linked with either compartmental or physiologically-based pharmacokinetics (PBPK) in GastroPlus, so you may predict your drug’s distribution and elimination once it enters into the systemic circulation.
For all of these PBPK delivery models, standard GastroPlus features, including the Population Simulator and Parameter Sensitivity Analysis, can be utilized. Plus, load measured in vivo PK data, for local tissues, to optimize and validate your models. And, finally, as with other GastroPlus modules, there is no equation or code writing required.
Resources
-
Fluorometholone Ocular Suspension PBPK simulations using the OCAT™ model in GastroPlus™
Learn MoreMichael B. Bolger, Jessica Spires, James M. Mullin, Joyce Macwan, Jayeeta Ghosh, Viera Lukacova
-
Physiologically-based pharmacokinetic (PBPK) model for prediction of tobramycin pulmonary absorption and pharmacokinetics in children
Learn MoreV. Lukacova, S. Ray Chaudhuri, W.S. Woltosz, M.B. Bolger
-
Physiologically-based pharmacokinetic (PBPK) model for prediction of midazolam pharmacokinetics after intranasal administration in children
Learn MoreViera Lukacova, Siladitya Ray Chaudhuri, Walter S. Woltosz , Michael B. Bolger
-
Development of a Novel Oral Cavity Compartmental Absorption and Transit Model for Sublingual Administration: Illustration with Zolpidem
Learn MoreXia B, Yang Z, Zhou H, Lukacova V, Zhu W, Milewski M, Kesisoglou F.
-
Physiologically based pharmacokinetic (PBPK) model to describe absorption and disposition of inhaled capreomycin
Learn MoreJames Mullin, Viera Lukacova, Michael Bolger, Walter Woltosz
